Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

In this study, the KPAI and KP-IGA scoring systems for assessing keratosis pilaris showed excellent interrater and intrarater reliability, offering standardized measures for clinical and research use.

This study observed that atopic dermatitis severity was associated with higher eosinophil counts and FLG variants, suggesting distinct endotypes that may require tailored treatment approaches.

A trial found that using finasteride, a hair growth drug, can be effectively measured by comparing before and after photos.

This study found that adherence to topical hydrocortisone in adults with atopic dermatitis was inconsistent and not significantly different across different medication vehicles, though disease severity improved markedly within 2 weeks.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

This study reports that dupilumab significantly reduced alopecia areata severity in pediatric patients with atopic dermatitis, indicating potential as an effective treatment option, though further research on long-term safety and optimal use is needed.

In this study, topical finasteride showed mild-to-moderate improvement in androgenetic alopecia among a cohort in Saudi Arabia, with combination therapy outperforming monotherapy. Adverse events were rare. The study highlights the need for prospective trials to clarify finasteride's standalone effects.

This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.

In this case series conducted in Austrian dermatology clinics, tralokinumab was found to be a well-tolerated and effective long-term treatment for adults with moderate-to-severe atopic dermatitis, with improvements in eczema severity and symptom suppression maintained over up to three years.

This study observed that combining botulinum toxin type A with Minoxidil significantly promoted hair growth, improved quality of life, and enhanced patient satisfaction in male androgenetic alopecia patients at 4 and 6 months, with no adverse effects compared to using Minoxidil alone.

In this study, a combination of GFM-lotion with autologous PRP treatment improved efficacy in treating androgenic alopecia compared to PRP alone, as shown by significant improvements in clinical assessments over 3 months.

This study reported that finasteride 1 mg significantly improved hair growth in men aged 41 to 60 with predominantly vertex male pattern hair loss over 24 months compared to placebo.

This study found that finasteride 1 mg per day improved hair growth and slowed hair loss in Japanese men with male pattern hair loss compared to lower doses and placebo.

In this study, untreated men with androgenetic alopecia continued to experience progressive hair loss over a 5-year period, with a significant decline in hair density observed in the placebo group.

This article reviews long-term data on the efficacy and safety of finasteride over five years but reports no new clinical results.

This study established an animal model using UV-irradiated C57BL/6 mice to assess hair luster, reporting that UV exposure alters keratin-associated protein gene expression, and suggested potential for developing effective hair care products by evaluating treatments like oral minoxidil.

This study found that 15% minoxidil topical solution was more effective than low-level laser therapy in improving hair regrowth and patient satisfaction in individuals with androgenetic alopecia.

This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.

In this study, experts propose a diagnostic and treatment guideline for folliculitis decalvans, emphasizing the role of trichoscopy and introducing a therapeutic algorithm tailored to disease activity, which is significant for clinical management given the lack of specific clinical trials.

In this study, Nd:YAG picosecond lasers using fractional micro-lens array were found to have a comparable effect to ablative fractional Er:YAG lasers in treating atrophic acne scars, with better safety profiles but slightly less patient satisfaction.

This study found that home-use microneedle devices combined with 5% minoxidil are not inferior to using 5% minoxidil alone for treating pattern hair loss, and may safely enhance hair growth.

In this study, the implementation of a nurse-led clinic effectively reduced waiting times for a tertiary hair and nails clinic, maintained manageable wait periods for 18 months, and provided satisfactory clinical and psychological support for patients with alopecia areata.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

This study found that laboratory testing practices for alopecia areata vary among international hair experts, with the majority routinely conducting thyroid function and complete blood count tests, yet exhibiting diverse approaches toward testing for other conditions or before prescribing systemic therapy.

This study confirmed that the Alopecia Areata-Investigator Global Assessment and other clinical outcome assessments are valid and relevant measures of treatment success for alopecia areata patients in Japan, aligning with previous North American findings.

In this study, researchers observed significant clinical improvement and patient satisfaction in the treatment of androgenic alopecia with a 1927-nm thulium laser, noting no adverse events and minimal pain across a short-term evaluation of ten patients.